CSIMarket
 


U s Stem Cell Inc   (USRM)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 

USRM's Net Cash Flow Growth by Quarter and Year

U S Stem Cell Inc 's Net Cash Flow results by quarter and year




USRM Net Cash Flow (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December 0.00 0.01 -0.06 -1.36
III Quarter September 0.03 -0.11 -0.07 0.77
II Quarter June 0.00 -0.31 0.12 -0.16
I Quarter March -0.02 0.43 0.03 -0.61
FY   0.01 0.02 0.02 -1.36



USRM Net Cash Flow fourth quarter 2022 Y/Y Growth Comment
U s Stem Cell Inc in the fourth quarter 2022 recorded net cash outflow of $ 0.00 millions.

According to the results reported in the fourth quarter 2022, U S Stem Cell Inc achieved the best Net Cash Flow growth in Medical Laboratories industry. While U S Stem Cell Inc ' s Net Cash Flow no change of % ranks overall at the positon no. in the fourth quarter 2022.




USRM Net Cash Flow ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - 1333.33 % - -
FY   -50 % -0 % - -

Financial Statements
U S Stem Cell Inc 's fourth quarter 2022 Net Cash Flow $ 0.00 millions USRM's Income Statement
U S Stem Cell Inc 's fourth quarter 2021 Net Cash Flow $ 0.01 millions Quarterly USRM's Income Statement
New: More USRM's historic Net Cash Flow Growth >>


USRM Net Cash Flow (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - 300 % -
I Quarter March - - - -
FY (Year on Year)   -50 % -0 % - -




Net Cash Flow fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #

Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Cash Flow fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Cash Flow by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

U S Stem Cell Inc 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


USRM's IV. Quarter Q/Q Net Cash Flow Comment
Recent accomplishment of 0.00 millions by U s Stem Cell Inc come out even more unfavourable if you take a look at 0.03 millions in the previous quarter.

Within Medical Laboratories industry U s Stem Cell Inc achieved highest sequential Net Cash Flow growth. While U S Stem Cell Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


USRM's IV. Quarter Q/Q Net Cash Flow Comment
IV. Quarter 2022 accomplishment of 0.00 millions by U s Stem Cell Inc appear even worse considering the 0.03 millions in the third quarter.

Within Medical Laboratories industry U s Stem Cell Inc achieved highest sequential Net Cash Flow growth. While U S Stem Cell Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


U S Stem Cell Inc 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
Cumulative Net Cash Flow 12 Months Ending $ 0.00 $ 0.01 $ -0.13 $ -0.43 $ 0.02
Y / Y Net Cash Flow Growth (TTM) - - - - 12.13 %
Year on Year Net Cash Flow Growth Overall Ranking # 346 # 344 # 0 # 0 # 348
Seqeuential Net Cash Flow Change (TTM) - - - - -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # # # # #




Cumulative Net Cash Flow growth Comment
U S Stem Cell Inc realized trailing twelve months net cash outflow of $ 0 millions, in the Dec 31 2022, compare to Net Cash Flow of $ 0 millions a year ago.

In the Healthcare sector 73 other companies have achieved higher trailing twelve month Net Cash Flow growth. While Net Cash Flow growth total ranking has deteriorated compare to previous quarter from 344 to 346.

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector # 74
Overall # 346

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
2041.58 %
32.37 %
-4400.32 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Cash Flow growth Comment
U S Stem Cell Inc realized trailing twelve months net cash outflow of $ 0 millions, in the Dec 31 2022, compare to Net Cash Flow of $ 0 millions a year ago.

In the Healthcare sector 73 other companies have achieved higher trailing twelve month Net Cash Flow growth. While Net Cash Flow growth total ranking has deteriorated compare to previous quarter from 344 to 346.

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector # 74
Overall # 346

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
2041.58 %
32.37 %
-4400.32 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Cash Flow Growth
Medical Laboratories Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
USRM's Net Cash Flow Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for USRM's Competitors
Net Cash Flow Growth for U S Stem Cell Inc 's Suppliers
Net Cash Flow Growth for USRM's Customers

You may also want to know
USRM's Annual Growth Rates USRM's Profitability Ratios USRM's Asset Turnover Ratio USRM's Dividend Growth
USRM's Roe USRM's Valuation Ratios USRM's Financial Strength Ratios USRM's Dividend Payout Ratio
USRM's Roa USRM's Inventory Turnover Ratio USRM's Growth Rates USRM's Dividend Comparisons



Companies with similar Net Cash Flow no change for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Dec 31 2022
Brainsway Ltd -0.24%$ -0.236 millions
Astrazeneca Plc-2.58%$ -2.575 millions
Nuvasive Inc-3.04%$ -3.040 millions
Purple Biotech Ltd -3.17%$ -3.174 millions
Mannkind Corporation-3.54%$ -3.545 millions
Calliditas Therapeutics Ab-4.09%$ -4.095 millions
Pharming Group N v -6.45%$ -6.451 millions
China Health Industries Holdings Inc -6.68%$ -6.684 millions
Galectin Therapeutics Inc -9.42%$ -9.416 millions
Cabaletta Bio Inc -10.05%$ -10.045 millions
Silk Road Medical Inc -11.70%$ -11.702 millions
Gsk Plc-12.89%$ -12.892 millions
Valneva Se-16.52%$ -16.515 millions
Inventiva S a -18.10%$ -18.104 millions
Xtl Biopharmaceuticals Ltd -18.23%$ -18.232 millions
Actavia Life Sciences Inc -19.83%$ -19.832 millions
Marpai Inc -20.85%$ -20.848 millions
Biolinerx Ltd -22.82%$ -22.821 millions
Ascendis Pharma A-23.65%$ -23.652 millions
Innate Pharma Sa-24.15%$ -24.151 millions
Apeiron Capital Investment Corp -26.15%$ -26.147 millions
Gilead Sciences Inc -26.95%$ -26.947 millions
4d Molecular Therapeutics Inc -27.91%$ -27.912 millions
American Shared Hospital Services-27.95%$ -27.945 millions
Koninklijke Philips Nv-28.61%$ -28.611 millions
Edap Tms Sa-29.06%$ -29.064 millions
Nanobiotix S a -29.57%$ -29.568 millions
Protagenic Therapeutics Inc new-29.84%$ -29.844 millions
Nucana Plc-31.01%$ -31.013 millions
Nls Pharmaceutics Ltd -34.10%$ -34.104 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com